Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effects of Vital Shower on Quality of Life, Immune Function, Cardiovascular Regulation and Well-being

NCT05328856 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2022-05-25
Last updated
2025-03-06

Condition(s) studied

General Population

Investigational drug(s) / intervention(s)

Hansgrohe prototype/shower head

Hansgrohe prototype/shower head: Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds

Study summary

The aim of this exploratory randomized controlled clinical study is to evaluate the health-promoting effects of Kneipp hydrotherapy, in the form of the Vital Shower in a four-week daily application.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female and male patients between 18 and 70 years of age Exclusion Criteria: * Bad general condition * Serious acute or chronic comorbidity * Pregnancy and breast feeding period/ in the next 6 months * Participation in a clinical trial within the last 3 months before enrollment * Simultaneous participation in another clinical trial * Raynaud's disease or cold agglutinin disease * Severe mental illness * Insufficiently treated dermatological diseases (e.g. neurodermatitis, psoriasis) * Non-compatible sanitary shower or bath devices

Primary outcome measure(s)

  • Immunological laboratory — Change from Baseline and after 4 weeks
    T-Cells (CD3), B-Cells (CD19), Natural Killer Cells (CD16), T-helper cells (CD4), cytotoxic T-cells (CD8), CD4/CD8 ratio, interleukin 4, interferon gamma
  • Blood pressure at rest (systolic and diastolic) — Change from Baseline and after 4 weeks
  • Hospital Anxiety and Depression Scale (HADS-D) — Change from HADS-D Baseline, after 4 weeks and 12 weeks
    Change
  • Self-Efficacy Scale (ASKU) — Change from ASKU Baseline, after 4 weeks and 12 weeks
    Change
  • WHO-Five Well-Being Index (WHO-5) — Change from WHO-5 Baseline, after 4 weeks and 12 weeks
    Change
  • Perceived Stress Scale (PSS-10) — Change from PSS-10 Baseline, after 4 weeks and 12 weeks
    Change
  • Flourishing Scale (FS-D) — Change from FS-D Baseline, after 4 weeks and 12 weeks
    Change
  • Insomnia Severity Index (ISI-D) — Change from ISI-D Baseline, after 4 weeks and 12 weeks
    Change
  • Short Form (SF-36) — Change from SF-36 Baseline, after 4 weeks and 12 weeks
    Change
  • Von Zerssen somatic complaint list (B-LR and B-LR') — Change from B-LR and B-LR' Baseline, after 4 weeks and 12 weeks
    Change
  • Heart rate variability — Change from Baseline and after 4 weeks
    Change

Trial sites (1)

FacilityCityRegionStatus
Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus Berlin State of Berlin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05328856 on ClinicalTrials.gov ↗ ← All trials in Germany